Oncolytics Biotech Inc (ONCY) Stock Price, Quote & News

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored...

Industry: Biotechnology

Sector: Healthcare

Phone: 403 670 7377

Fax: 403 283 0858

Website: oncolyticsbiotech.com

Address:

4350 Executive Drive, Suite 325, San Deigo, United States

saxy4u Jun. 4 at 1:58 AM

$ONCY Final thought and hope for the morning! Final Protocol for Anal before the 1V1 Jeffries meetings. I believe something big will happen in the morning, maybe even partner (I hope) before meeting with the Tutes! Maybe Patent approvals. Something will/should come out. The new Grants show that they aren’t doing all this to close shop, this could be huge!(I hope)!

1 · Reply

saxy4u Jun. 4 at 1:07 AM

$ONCY remember share grants are how these guys are getting paid every year!

1 · Reply

De_man Jun. 4 at 12:58 AM

$ONCY yikes, thanks fox ,I just found all the other filings and everyone got new options it would appear.

2 · Reply

De_man Jun. 4 at 12:54 AM

$ONCY I have not seen the new award of options to jared Kelly. The new sec filing that I got today only showed the new guy , Stephen Glover with a grant of 96k options at an exercise price of 1.06. If there are more filings fox could u please give the particulars or links to the filings.

0 · Reply

saxy4u Jun. 4 at 12:48 AM

$ONCY https://www.linkedin.com/posts/jared-kelly-53370934_crc-scac-pdac-share-7467969908421591040-RWck/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAZPeTUB2cyiOZxf0FYiQiXQJIZPwU5o3JY&utm_campaign=copy_link

0 · Reply

FoxM07 Jun. 3 at 11:49 PM

$ONCY 755,000 grant of options awarded to J. Kelly...i guess for his impressive work towards shareholder value.

1 · Reply

FoxM07 Jun. 3 at 7:22 PM

$ONCY SMMT $11.5B. Oncy...$100M. Don't compare success to abject failure.

1 · Reply

Notable_Ex Jun. 3 at 6:28 PM

$ONCY Fuzzyballs is all that he admits to being.

0 · Reply

FoxM07 Jun. 3 at 5:29 PM

$ONCY SMMT has a market cap of $11.5b. Oncy has a market cap of $100M. Get real, be honest and stop the unhinged and unwarranted comparisons.

1 · Reply

FoxM07 Jun. 3 at 5:27 PM

$ONCY the paid pumpers are indeed flailing with conspiracy theory after conspiracy theory. I guess im now a Chinese spy who traveled to India to short as part of a cold room team. Seems likely, and entirely unhealthy lol.

2 · Reply

Oncolytics promotes John McAdory to COO

CGON

Jun 2, 2026, 9:00 AM EDT - 1 day ago

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

2026-06-01T13:47:40.000Z - 2 days ago

Oncolytics announces initial data from pelareorep combination study

Jun 1, 2026, 9:00 AM EDT - 2 days ago

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

2026-05-22T13:45:50.000Z - 12 days ago

Oncolytics Biotech to present data at ASCO 2026 on pelareorep

May 22, 2026, 9:00 AM EDT - 12 days ago

Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors

May 14, 2026, 4:00 PM EDT - 20 days ago

Oncolytics Biotech Quarterly report: Q1 2026

May 4, 2026, 9:00 AM EDT - 4 weeks ago

Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer

2026-04-27T13:19:05.000Z - 5 weeks ago

Oncolytics says in alignment with FDA following pelareorep Type C meeting

Apr 27, 2026, 8:10 AM EDT - 5 weeks ago

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026, 7:00 AM EDT - 5 weeks ago

Oncolytics Biotech Slides: Corporate presentation

2026-04-07T14:24:37.000Z - 2 months ago

Oncolytics price target lowered to $5 from $7 at Lake Street

2026-04-06T13:56:11.000Z - 2 months ago

Oncolytics schedules FDA meeting for pelareorep registrational path

Apr 6, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

2026-04-01T13:39:37.000Z - 2 months ago

Oncolytics completes domicile change to the U.S.

Apr 1, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® Completes Domicile Change to the United States

Apr 1, 2026, 8:00 AM EDT - 2 months ago

Oncolytics Biotech Registration statement: Registration filing

2026-04-01T10:11:38.000Z - 2 months ago

Oncolytics files $250M mixed securities shelf

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Oncolytics Biotech Annual report: Q4 2025

2026-03-19T13:16:47.000Z - 2 months ago

Oncolytics to present new data on Pelareorep at AACR 2026

Mar 19, 2026, 9:00 AM EDT - 2 months ago

Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026

Mar 3, 2026, 6:00 AM EST - 3 months ago

Oncolytics Biotech Slides: Corporate presentation

2026-03-02T14:12:44.000Z - 3 months ago

Oncolytics initiates randomized colorectal cancer study

Mar 2, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® Launches Randomized Colorectal Cancer Study

2026-02-24T14:05:55.000Z - 3 months ago

Oncolytics concludes enrollment in GOBLET study

Feb 24, 2026, 9:00 AM EST - 3 months ago

Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer

2026-02-04T13:55:27.000Z - 4 months ago

Oncolytics receives FDA Fast Track Designation for pelareorep

Feb 4, 2026, 8:50 AM EST - 4 months ago

Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer

Jan 15, 2026, 4:01 PM EST - 4 months ago

Oncolytics Biotech® Announces Results of Special Meeting of Shareholders

Jan 15, 2026, 10:00 AM EST - 4 months ago

Oncolytics Biotech Transcript: AGM 2026

2026-01-14T14:15:39.000Z - 5 months ago

Oncolytics appoints John McAdory as EVP, strategy and operations

CGON

Jan 14, 2026, 7:00 AM EST - 5 months ago

Oncolytics Biotech Slides: Investor presentation

2026-01-12T14:10:53.000Z - 5 months ago

Oncolytics announces updates data from GOBLET cohort 4

Jan 12, 2026, 9:00 AM EST - 5 months ago

Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

2026-01-09T14:05:19.000Z - 5 months ago

Oncolytics outlines strategic rationale for proposal to change jurisdiction

Jan 9, 2026, 9:00 AM EST - 5 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

Jan 8, 2026, 9:00 AM EST - 5 months ago

Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings

Jan 7, 2026, 9:00 AM EST - 5 months ago

Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris

2025-12-16T14:20:43.000Z - 6 months ago

Oncolytics reports clinical, translational findings from pelareorep development

Dec 16, 2025, 9:00 AM EST - 6 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

Dec 9, 2025, 6:00 PM EST - 6 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

Nov 20, 2025, 4:05 PM EST - 6 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

2025-11-19T14:10:13.000Z - 7 months ago

Oncolytics aligns with FDA on pelareorep study design

Nov 19, 2025, 9:00 AM EST - 7 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

2025-11-17T11:20:37.000Z - 7 months ago

Oncolytics price target raised to $10 from $5 at H.C. Wainwright

Nov 11, 2025, 6:00 PM EST - 7 months ago

Oncolytics Biotech Earnings release: Q3 2025

2025-10-28T11:35:27.000Z - 7 months ago

Oncolytics reports updated results from study of pelareorep plus atezolizumab

Oct 28, 2025, 7:30 AM EDT - 7 months ago

Oncolytics Biotech® Reports Updated Anal Cancer Data Showing Objective Response Rate More Than Double the Current Standard of Care

Oct 20, 2025, 9:00 AM EDT - 8 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Oncolytics Biotech® Announces Update for Potential First-Line Pancreatic Cancer Registration Study

Sep 16, 2025, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Oncolytics Biotech® Highlights Strong Efficacy and Translational Data in Metastatic Colorectal Cancer; Will Advance Regulatory Pathway Discussions

Sep 2, 2025, 9:10 AM EDT - 9 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

Aug 28, 2025, 8:30 AM EDT - 9 months ago

Oncolytics Biotech® Announces Upcoming Investor Conferences in September

Aug 22, 2025, 8:00 AM EDT - 10 months ago

Oncolytics Biotech Registration statement: Registration Filing

Aug 11, 2025, 4:55 PM EDT - 10 months ago

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Aug 8, 2025, 10:00 AM EDT - 10 months ago

Oncolytics Biotech Transcript: AGM 2025

Aug 8, 2025, 10:00 AM EDT - 10 months ago

Oncolytics Biotech Earnings release: Q2 2025

Aug 8, 2025, 9:05 AM EDT - 10 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

Aug 8, 2025, 9:00 AM EDT - 10 months ago

Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Jul 29, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

Jul 23, 2025, 9:39 AM EDT - 11 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

Jul 22, 2025, 3:32 PM EDT - 11 months ago

Oncolytics Biotech® Regains Compliance with Nasdaq Trading Rules

Jul 22, 2025, 1:00 PM EDT - 11 months ago

Oncolytics Biotech Transcript: Status Update

Jul 16, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

Jul 10, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® to Host Key Opinion Leader Discussion Focusing on Pancreatic and Gastrointestinal Cancers

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

Jun 30, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

Jun 11, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® Names New CEO to Accelerate Momentum in Immunotherapy Programs

May 23, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q1 2025

May 14, 2025, 4:01 PM EDT - 1 year ago

Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

May 6, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights

Apr 24, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

Apr 10, 2025, 6:09 PM EDT - 1 year ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

Apr 10, 2025, 7:00 AM EDT - 1 year ago

Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Annual report: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings release: Q4 2024

Mar 7, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

Feb 25, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights

Feb 19, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

Feb 18, 2025, 7:00 AM EST - 1 year ago

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Feb 14, 2025, 5:15 PM EST - 1 year ago

Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

saxy4u Jun. 4 at 1:58 AM

1 · Reply

saxy4u Jun. 4 at 1:07 AM

$ONCY remember share grants are how these guys are getting paid every year!

1 · Reply

De_man Jun. 4 at 12:58 AM

$ONCY yikes, thanks fox ,I just found all the other filings and everyone got new options it would appear.

2 · Reply

De_man Jun. 4 at 12:54 AM

0 · Reply

saxy4u Jun. 4 at 12:48 AM

0 · Reply

FoxM07 Jun. 3 at 11:49 PM

$ONCY 755,000 grant of options awarded to J. Kelly...i guess for his impressive work towards shareholder value.

1 · Reply

FoxM07 Jun. 3 at 7:22 PM

$ONCY SMMT $11.5B. Oncy...$100M. Don't compare success to abject failure.

1 · Reply

Notable_Ex Jun. 3 at 6:28 PM

$ONCY Fuzzyballs is all that he admits to being.

0 · Reply

FoxM07 Jun. 3 at 5:29 PM

$ONCY SMMT has a market cap of $11.5b. Oncy has a market cap of $100M. Get real, be honest and stop the unhinged and unwarranted comparisons.

1 · Reply

FoxM07 Jun. 3 at 5:27 PM

2 · Reply

Notable_Ex Jun. 3 at 5:23 PM

$ONCY Well now we see why Fuzzyballs has been defending the Chinese assets being developed by RVMD and SMMT so vorciferously. Not only are their assets Chinese, but also because that in June 2025 RVMD and SMMT entered into a clinical development deal in multiple cancers. The clinical collaboration aims to evaluate these combinations across three priority tumor types including RAS mutant non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC). https://www.businesswire.com/news/home/20250630429894/en/Revolution-Medicines-and-Summit-Therapeutics-Enter-Into-Clinical-Collaboration-to-Evaluate-Combinations-of-Three-RASON-Inhibitors-With-Ivonescimab-in-RAS-Mutant-Tumors

0 · Reply

FoxM07 Jun. 3 at 5:19 PM

$ONCY nobody is doubting SMMT, thats pure deflection by the exposed paid pumper. SMMT is trading at almost $15 usd per share, has a market cap of $11.5b & was incorporated in 2020. Oncy, the 30 yr old forgotten story is once again trading at ninety cents with a market cap of $100M. Now, who's doubting who? Lol...

1 · Reply

Notable_Ex Jun. 3 at 5:09 PM

$ONCY Amid the rounds of applause at ASCO and the stream of multibillion-dollar transactions, doubts and uncertainties linger around SMMT's PD-1 x VEGF bispecific ivonescimab. Despite a positive OS readout from Harmoni-6 that exceeded expectations, Akeso’s stock price first shot up then dropped Monday as its findings’ translatability from China to a global population came into question. “It’s not necessarily a China question versus a non-China question,” Merck’s Green said. “It has to do with, when you do studies in more homogeneous settings or in smaller groups. There's similar questions to me about, how do things translate when you take it into a broader global study where you’ve got more heterogeneity of care?”

1 · Reply

FoxM07 Jun. 3 at 4:49 PM

$ONCY great, but this holds little to no relevance to Oncy. Hopefully mCRC produces enough positive results for majors to have more than a cursory interest in pela/Oncy. We won't get an Innovent type deal, but perhaps 5%-10% of that. Fingers crossed longs!

1 · Reply

Notable_Ex Jun. 3 at 4:41 PM

$ONCY June 03, 2026 - “China is no longer what you would call the bargain basement anymore,” Li Watsek, a senior biotech analyst at Cantor Fitzgerald, told Biospace. She observed that total deal value for China-developed assets has caught up to similar deals outside the country since the second half of 2025. Big Pharmas are no longer as eager as before to cut deals on early clinical candidates with Chinese biotechs. In Jefferies Cui Cui, Head of Asia Healthcare Research view, that’s because the low-hanging fruits there are pretty much all picked. Another shift in the U.S.-China licensing deals is the transaction model. Platform deals now have replaced single-asset licensing from earlier waves and become the dominant transaction model, as noted by analysts." https://www.biospace.com/business/no-longer-a-bargain-pool-chinese-biotechs-command-higher-premiums

1 · Reply

oncoholic Jun. 3 at 4:34 PM

$ONCY

0 · Reply

JohnnyC63 Jun. 3 at 4:05 PM

$ONCY Tell me ONCY isn’t heavily manipulated without saying "ONCY is heavily manipulated"...

2 · Reply

saxy4u Jun. 3 at 3:42 PM

$ONCY Word of the Year is "Conjecture". Find something new...Boring!!

1 · Reply

FoxM07 Jun. 3 at 3:35 PM

$ONCY anyone that isn't disgruntled after 30 years of zero shareholder value is a daytrading pumper who should be reported for conjecture, spam and a general lack of education. I guess an earnest long shouldn't be frustrated when new biotechs make billions as this 30 yr old penny stock continues to fumble the ball.

1 · Reply

saxy4u Jun. 3 at 3:24 PM

$ONCY Let's take the opportunity to revisit, Fox (India Call Centre), Manipulation of ONCY share price. Daily 50-150,000 shares are short sold at 10 am, recovers over the day bringing it back to $.02 short of beguinning of the day, sometimes higher. Trashes the ownership daily and anyone that is positive towards the advancement of the product. Do yourself a favor and all the rest of us. Block and Report for Conjecture.

1 · Reply

FoxM07 Jun. 3 at 2:46 PM

$ONCY let's take this opportunity to revisit the pump that dominated Q1 of '26: redomiciling. The preeminent pump crew (saxy, canadafan & notable) took to posting everyday that the Nevada move would guarantee more $$$ exposure & that Oncy shareholders would benefit to the tune of a $3.55 usd SP by end of Feb, and a $10 usd SP by April. I need not remind anyone of the stagnant SP. Try some credibility & integrity pumpers.

1 · Reply

FoxM07 Jun. 3 at 1:59 PM

$ONCY great conjecture but its mCRC or nothing. A one trick pony. MBC and PDAC are on ice due to Dara and Enhertu. Truth.

1 · Reply

Market Cap	124.13M
Revenue (ttm)	0.00
Net Income (ttm)	-28.76M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,559,200
Avg Vol	1,095,428
Day's Range	N/A - N/A
Shares Out	119.35M
Stochastic %K	90%
Beta	1.02
Analysts	Strong Sell
Price Target	$4.87